JP2006516038A - 生合成基質およびその用法 - Google Patents
生合成基質およびその用法 Download PDFInfo
- Publication number
- JP2006516038A JP2006516038A JP2004526538A JP2004526538A JP2006516038A JP 2006516038 A JP2006516038 A JP 2006516038A JP 2004526538 A JP2004526538 A JP 2004526538A JP 2004526538 A JP2004526538 A JP 2004526538A JP 2006516038 A JP2006516038 A JP 2006516038A
- Authority
- JP
- Japan
- Prior art keywords
- synthetic copolymer
- substrate
- biopolymer
- collagen
- biosynthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 184
- 230000001851 biosynthetic effect Effects 0.000 title claims abstract description 83
- 239000000017 hydrogel Substances 0.000 claims abstract description 116
- 229920001222 biopolymer Polymers 0.000 claims abstract description 66
- 239000012867 bioactive agent Substances 0.000 claims abstract description 53
- 239000011159 matrix material Substances 0.000 claims abstract description 40
- 238000004132 cross linking Methods 0.000 claims abstract description 37
- 238000001727 in vivo Methods 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims description 99
- 102000008186 Collagen Human genes 0.000 claims description 99
- 229920001436 collagen Polymers 0.000 claims description 99
- 229920001577 copolymer Polymers 0.000 claims description 85
- 239000007943 implant Substances 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 73
- 210000004087 cornea Anatomy 0.000 claims description 44
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 39
- 150000003926 acrylamides Chemical class 0.000 claims description 37
- -1 methacrylic carboxylic acid Chemical class 0.000 claims description 32
- 239000003125 aqueous solvent Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- YXMISKNUHHOXFT-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) prop-2-enoate Chemical compound C=CC(=O)ON1C(=O)CCC1=O YXMISKNUHHOXFT-UHFFFAOYSA-N 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003999 initiator Substances 0.000 claims description 9
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 8
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 claims description 7
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 7
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012964 benzotriazole Substances 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- JMCVCHBBHPFWBF-UHFFFAOYSA-N n,n-diethyl-2-methylprop-2-enamide Chemical compound CCN(CC)C(=O)C(C)=C JMCVCHBBHPFWBF-UHFFFAOYSA-N 0.000 claims description 4
- OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 229960002317 succinimide Drugs 0.000 claims description 3
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 claims description 2
- BLSAPDZWVFWUTL-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OS(=O)(=O)C1CC(=O)NC1=O BLSAPDZWVFWUTL-UHFFFAOYSA-N 0.000 claims description 2
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 claims description 2
- YQIGLEFUZMIVHU-UHFFFAOYSA-N 2-methyl-n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C(C)=C YQIGLEFUZMIVHU-UHFFFAOYSA-N 0.000 claims description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- WFKDPJRCBCBQNT-UHFFFAOYSA-N n,2-dimethylprop-2-enamide Chemical compound CNC(=O)C(C)=C WFKDPJRCBCBQNT-UHFFFAOYSA-N 0.000 claims description 2
- QRWZCJXEAOZAAW-UHFFFAOYSA-N n,n,2-trimethylprop-2-enamide Chemical compound CN(C)C(=O)C(C)=C QRWZCJXEAOZAAW-UHFFFAOYSA-N 0.000 claims description 2
- SAEXFKSTXQREHP-UHFFFAOYSA-N n,n-dicyclohexylprop-2-enamide Chemical compound C1CCCCC1N(C(=O)C=C)C1CCCCC1 SAEXFKSTXQREHP-UHFFFAOYSA-N 0.000 claims description 2
- LHLLNIZKYYRADT-UHFFFAOYSA-N n-cyclohexyl-n-methylprop-2-enamide Chemical compound C=CC(=O)N(C)C1CCCCC1 LHLLNIZKYYRADT-UHFFFAOYSA-N 0.000 claims description 2
- PMJFVKWBSWWAKT-UHFFFAOYSA-N n-cyclohexylprop-2-enamide Chemical compound C=CC(=O)NC1CCCCC1 PMJFVKWBSWWAKT-UHFFFAOYSA-N 0.000 claims description 2
- ZIWDVJPPVMGJGR-UHFFFAOYSA-N n-ethyl-2-methylprop-2-enamide Chemical compound CCNC(=O)C(C)=C ZIWDVJPPVMGJGR-UHFFFAOYSA-N 0.000 claims description 2
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 claims description 2
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 claims description 2
- AWGZKFQMWZYCHF-UHFFFAOYSA-N n-octylprop-2-enamide Chemical compound CCCCCCCCNC(=O)C=C AWGZKFQMWZYCHF-UHFFFAOYSA-N 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 abstract description 92
- 231100000433 cytotoxic Toxicity 0.000 abstract description 4
- 230000001472 cytotoxic effect Effects 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 description 68
- 210000001519 tissue Anatomy 0.000 description 49
- 229920001897 terpolymer Polymers 0.000 description 43
- 239000000178 monomer Substances 0.000 description 41
- 239000002953 phosphate buffered saline Substances 0.000 description 31
- 239000000499 gel Substances 0.000 description 29
- 210000005036 nerve Anatomy 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- UFHSKEHEWFGEFH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-3-yl) prop-2-enoate Chemical compound C=CC(=O)OC1CC(=O)NC1=O UFHSKEHEWFGEFH-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000010186 staining Methods 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 238000002054 transplantation Methods 0.000 description 18
- 210000000981 epithelium Anatomy 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000010261 cell growth Effects 0.000 description 15
- 238000010561 standard procedure Methods 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- 230000005540 biological transmission Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000035699 permeability Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 210000002469 basement membrane Anatomy 0.000 description 8
- 238000004624 confocal microscopy Methods 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 210000000301 hemidesmosome Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000002241 neurite Anatomy 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 7
- GNWBLLYJQXKPIP-ZOGIJGBBSA-N (1s,3as,3bs,5ar,9ar,9bs,11as)-n,n-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1h-indeno[5,4-f]quinoline-1-carboxamide Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(CC)CC)[C@@]2(C)CC1 GNWBLLYJQXKPIP-ZOGIJGBBSA-N 0.000 description 6
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 229920001519 homopolymer Polymers 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 229920005604 random copolymer Polymers 0.000 description 6
- 210000002536 stromal cell Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000007547 Laminin Human genes 0.000 description 5
- 108010085895 Laminin Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000000149 argon plasma sintering Methods 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 210000003560 epithelium corneal Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004510 Collagen Type VII Human genes 0.000 description 3
- 108010017377 Collagen Type VII Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 108010015046 cell aggregation factors Proteins 0.000 description 3
- 239000011557 critical solution Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- MZHBJMCGUSCOJN-UHFFFAOYSA-N 2-[(2-cyanocyclohexyl)diazenyl]cyclohexane-1-carbonitrile Chemical compound N#CC1CCCCC1N=NC1C(C#N)CCCC1 MZHBJMCGUSCOJN-UHFFFAOYSA-N 0.000 description 1
- AOUXPMZVVLSMQQ-UHFFFAOYSA-N 2-[(2-cyanocyclooctyl)diazenyl]cyclooctane-1-carbonitrile Chemical compound N#CC1CCCCCCC1N=NC1C(C#N)CCCCCC1 AOUXPMZVVLSMQQ-UHFFFAOYSA-N 0.000 description 1
- RUECTJATXCACED-UHFFFAOYSA-N 2-aminoacetic acid;hydrate Chemical compound [OH-].[NH3+]CC(O)=O RUECTJATXCACED-UHFFFAOYSA-N 0.000 description 1
- XIXPBVLOLRFPNE-UHFFFAOYSA-N 2-cyclopropylpropanenitrile Chemical compound N#CC(C)C1CC1 XIXPBVLOLRFPNE-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 231100000694 OECD Guidelines for the Testing of Chemicals Toxicity 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229920005605 branched copolymer Polymers 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- MKUWVMRNQOOSAT-UHFFFAOYSA-N but-3-en-2-ol Chemical compound CC(O)C=C MKUWVMRNQOOSAT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- ZOTWHNWBICCBPC-UHFFFAOYSA-N n-ethyl-n-methylprop-2-enamide Chemical compound CCN(C)C(=O)C=C ZOTWHNWBICCBPC-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007586 pull-out test Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 210000002341 stratified epithelial cell Anatomy 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F246/00—Copolymers in which the nature of only the monomers in minority is defined
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Eyeglasses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2397379 | 2002-08-09 | ||
| PCT/CA2003/001180 WO2004014969A1 (en) | 2002-08-09 | 2003-08-11 | Bio-synthetic matrix and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007273082A Division JP2008093451A (ja) | 2002-08-09 | 2007-10-19 | 眼用インプラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516038A true JP2006516038A (ja) | 2006-06-15 |
| JP2006516038A5 JP2006516038A5 (es) | 2006-10-05 |
Family
ID=31501599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526538A Pending JP2006516038A (ja) | 2002-08-09 | 2003-08-11 | 生合成基質およびその用法 |
| JP2007273082A Pending JP2008093451A (ja) | 2002-08-09 | 2007-10-19 | 眼用インプラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007273082A Pending JP2008093451A (ja) | 2002-08-09 | 2007-10-19 | 眼用インプラント |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20060134050A1 (es) |
| EP (2) | EP1741457A1 (es) |
| JP (2) | JP2006516038A (es) |
| KR (1) | KR101053792B1 (es) |
| CN (1) | CN100491424C (es) |
| AT (1) | ATE356838T1 (es) |
| AU (1) | AU2003254674A1 (es) |
| BR (1) | BR0313726A (es) |
| DE (1) | DE60312525T2 (es) |
| ES (1) | ES2283849T3 (es) |
| HK (1) | HK1078886A1 (es) |
| MX (1) | MXPA05001570A (es) |
| WO (1) | WO2004014969A1 (es) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006513744A (ja) * | 2002-12-19 | 2006-04-27 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド | 親水性コーティングを備えた生物医学装置 |
| JP2006515685A (ja) * | 2002-12-23 | 2006-06-01 | アルコン、インコーポレイテッド | 表面へのタンパク質吸着を抑制するためのｎ−イソプロピルアクリルアミド含有組成物および方法 |
| JP2007126490A (ja) * | 2005-11-01 | 2007-05-24 | Univ Of Tokushima | アミド基含有高分子化合物およびその製造方法 |
| WO2009034958A1 (ja) * | 2007-09-12 | 2009-03-19 | Jsr Corporation | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05002669A (es) * | 2002-09-13 | 2005-08-19 | Ocular Sciences Inc | Dispositivos y metodos para mejorar la vision. |
| US7628810B2 (en) | 2003-05-28 | 2009-12-08 | Acufocus, Inc. | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
| US20050046794A1 (en) | 2003-06-17 | 2005-03-03 | Silvestrini Thomas A. | Method and apparatus for aligning a mask with the visual axis of an eye |
| WO2005095441A1 (ja) * | 2004-03-31 | 2005-10-13 | National Institute Of Advanced Industrial Science And Technology | 上皮系細胞増殖促進剤 |
| CN101018513B (zh) * | 2004-08-13 | 2011-11-16 | 渥太华健康研究所 | 视力增强眼科器件及相关方法和组合物 |
| US8246569B1 (en) | 2004-08-17 | 2012-08-21 | California Institute Of Technology | Implantable intraocular pressure drain |
| KR101159071B1 (ko) * | 2005-01-14 | 2012-06-26 | 삼성전자주식회사 | 신규한 히드로겔 공중합체, 상기 공중합체가 코팅되어있는 기판, 상기 공중합체를 이용하여 마이크로어레이를제조하는 방법 및 그에 의하여 제조된 마이크로어레이 |
| US9999497B2 (en) * | 2005-01-31 | 2018-06-19 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
| US7976577B2 (en) * | 2005-04-14 | 2011-07-12 | Acufocus, Inc. | Corneal optic formed of degradation resistant polymer |
| US20070148246A1 (en) * | 2005-08-11 | 2007-06-28 | Dan Luo | Nucleic Acid-Based Matrixes |
| CA2621824C (en) * | 2005-09-09 | 2014-10-07 | Ottawa Health Research Institute | Interpenetrating networks, and related methods and compositions |
| ES2493921T3 (es) | 2006-03-14 | 2014-09-12 | University Of Southern California | Dispositivo MEMS para la administración de agentes terapéuticos |
| US7883520B2 (en) | 2006-04-10 | 2011-02-08 | Forsight Labs, Llc | Corneal epithelial pocket formation systems, components and methods |
| US8889791B2 (en) * | 2006-10-10 | 2014-11-18 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Thermoresponsive, biodegradable, elastomeric material |
| EP2111239B1 (en) | 2006-12-15 | 2013-03-06 | Lifebond Ltd. | Gelatin-transglutaminase hemostatic dressings and sealants |
| US20080274054A1 (en) * | 2007-05-01 | 2008-11-06 | Taipei Veterans General Hospital | Composite for Thermo-Sensitive Cell-Tissue Transplanted Scaffold and Use thereof |
| US20100178316A1 (en) * | 2007-05-30 | 2010-07-15 | Anuj Chauhan | Extended release of bioactive molecules from silicone hydrogels |
| WO2008154412A2 (en) * | 2007-06-06 | 2008-12-18 | Stc.Unm | Bio-compatible hybrid organic/inorganic gels:vapor phase synthesis |
| US11083190B2 (en) * | 2007-06-29 | 2021-08-10 | Makoto Funaki | Soft gel systems in modulating stem cell development |
| US8075909B2 (en) * | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
| WO2009042768A1 (en) * | 2007-09-25 | 2009-04-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Triggerably dissolvable hollow fibers for controlled delivery |
| CN101396569B (zh) * | 2007-09-27 | 2013-04-10 | 北京师范大学 | 以生物体组织为支架的复合水凝胶、其制备方法及其用途 |
| US8293510B2 (en) * | 2007-11-16 | 2012-10-23 | University Of Kansas | Method of preparing a hydrogel network encapsulating cells |
| MX2010006840A (es) | 2007-12-20 | 2010-08-12 | Univ Southern California | Aparato y métodos para suministrar agentes terapeuticos. |
| MX2010007382A (es) | 2008-01-03 | 2010-12-20 | Univ Southern California | Dispositivos implantables para suministro de farmacos, y aparato y metodos para recargar los dispositivos. |
| CA2714010C (en) | 2008-01-30 | 2020-06-16 | Corning Incorporated | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| US8354274B2 (en) * | 2008-01-30 | 2013-01-15 | Geron Corporation | Synthetic surfaces for culturing cells in chemically defined media |
| US8329469B2 (en) * | 2008-01-30 | 2012-12-11 | Geron Corporation | Swellable (meth)acrylate surfaces for culturing cells in chemically defined media |
| WO2009099539A2 (en) * | 2008-01-30 | 2009-08-13 | Corning Incorporated | (meth)acrylate surfaces for cell culture, methods of making and using the surfaces |
| SG188098A1 (en) * | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived cardiomyocytes |
| WO2009102952A2 (en) | 2008-02-13 | 2009-08-20 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
| FR2927902B1 (fr) * | 2008-02-26 | 2011-11-11 | Oreal | Polymere ethylenique statistique comprenant un groupe reactif et un groupe ionisable, composition cosmetique et procede de traitement cosmetique. |
| US9943401B2 (en) | 2008-04-04 | 2018-04-17 | Eugene de Juan, Jr. | Therapeutic device for pain management and vision |
| US8083347B2 (en) * | 2008-04-29 | 2011-12-27 | Ocugenics, LLC | Drug delivery system and methods of use |
| US8361492B2 (en) * | 2008-04-29 | 2013-01-29 | Ocugenics, LLC | Drug delivery system and methods of use |
| ES2534864T3 (es) | 2008-05-08 | 2015-04-29 | Minipumps, Llc | Bombas implantables y cánulas para las mismas |
| WO2009137777A2 (en) | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
| US8231609B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
| WO2009137829A2 (en) * | 2008-05-09 | 2009-11-12 | Wake Forest University Health Sciences | Directed stem cell recruitment |
| CN102124058B (zh) | 2008-06-18 | 2014-05-28 | 生命连结有限公司 | 改进的交联组合物 |
| US20100080840A1 (en) * | 2008-07-31 | 2010-04-01 | Michael Cho | Hybrid superporous hydrogel scaffold for cornea regeneration |
| US20110269208A1 (en) * | 2008-08-15 | 2011-11-03 | The Trustees Of The University Of Pennsylvania | Cross-linked polymer network formed by sequential cross-linking |
| FR2938544B1 (fr) * | 2008-11-20 | 2011-01-21 | Univ Cergy Pontoise | Materiaux sous forme de reseaux interpenetres de polymeres associant un gel de fibrine et un reseau de polyethylene glycol |
| US8109997B2 (en) * | 2009-01-18 | 2012-02-07 | Eyeon Medical Ltd. | Hydrophobic pseudo-endothelial implants for treating corneal edema |
| CN101543642B (zh) * | 2009-04-02 | 2012-06-27 | 天津大学 | 胶原基互穿聚合物网络组织工程角膜替代物及其制备方法 |
| US8673295B2 (en) * | 2009-04-30 | 2014-03-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Thermoresponsive, biodegradable, elastomeric material and uses therefor |
| US8362144B2 (en) * | 2009-05-21 | 2013-01-29 | Corning Incorporated | Monomers for making polymeric cell culture surface |
| US20120142069A1 (en) * | 2009-07-08 | 2012-06-07 | Northwestern University | Interpenetrating biomaterial matrices and uses thereof |
| BR112012008079A2 (pt) | 2009-08-13 | 2016-03-01 | Acufocus Inc | enxerto de córnea com estruturas de transporte de nutrientes |
| AU2010282311B2 (en) | 2009-08-13 | 2015-08-13 | Acufocus, Inc. | Masked intraocular implants and lenses |
| US10004593B2 (en) | 2009-08-13 | 2018-06-26 | Acufocus, Inc. | Intraocular lens with elastic mask |
| CN102576385B (zh) | 2009-08-18 | 2016-02-24 | 迷你泵有限责任公司 | 具有自适应控制的电解药物输送泵 |
| NO2490635T3 (es) | 2009-10-23 | 2018-02-03 | ||
| EP2490620A4 (en) | 2009-10-23 | 2017-03-22 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
| EP2515957B1 (en) | 2009-12-22 | 2015-07-29 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
| US9376661B2 (en) * | 2010-02-05 | 2016-06-28 | Cornea Regeneration Institute Co., Ltd. | Method for culture of corneal endothelial cells, process for production of corneal endothelial cell sheet for transplantation purposes, and culture kit for corneal endothelial cells |
| WO2011105724A2 (ko) * | 2010-02-24 | 2011-09-01 | 주식회사 티이바이오스 | 관절연골 재생용 지지체 및 이의 제조방법 |
| CN103118713B (zh) | 2010-08-05 | 2016-06-01 | 生命连结有限公司 | 干组合物伤口敷料及粘合剂 |
| AU2011289214B2 (en) | 2010-08-13 | 2015-05-28 | Wake Forest University Health Sciences | Methods for making a tissue engineered muscle repair (TEMR) construct in vitro for implantation in vivo |
| WO2012024390A2 (en) | 2010-08-17 | 2012-02-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biohybrid composite scaffold |
| EP3730093B1 (en) | 2010-09-30 | 2022-12-21 | KeraMed, Inc. | Reversibly deformable artificial cornea |
| US8871016B2 (en) | 2011-08-03 | 2014-10-28 | The Johns Hopkins University | Cellulose-based hydrogels and methods of making thereof |
| US9175153B2 (en) | 2011-03-08 | 2015-11-03 | The Johns Hopkins University | Cellulose hydrogel compositions and contact lenses for corneal applications |
| US9211256B2 (en) | 2011-03-08 | 2015-12-15 | The Johns Hopkins University | Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof |
| US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
| WO2013082545A1 (en) | 2011-12-02 | 2013-06-06 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
| CN103204971B (zh) * | 2013-01-16 | 2014-12-10 | 北京科技大学 | 基于硝基苯的三重响应聚合物自组装体的制备方法和应用 |
| RU2513838C1 (ru) * | 2013-02-21 | 2014-04-20 | Общество с ограниченной ответственностью "ДЖИ-Групп" | Гистоэквивалент-биопластический материал |
| US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
| US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US9956168B2 (en) | 2013-06-20 | 2018-05-01 | Mercy Medical Research Institute | Extended release drug-delivery contact lenses and methods of making |
| EP3014345A2 (en) | 2013-06-26 | 2016-05-04 | Nexisvision, Inc. | Contact lenses for refractive correction |
| US9512279B2 (en) * | 2013-12-18 | 2016-12-06 | Universite Cegy-Pontoise | Interpenetrating polymer network |
| SG11201606729XA (en) | 2014-02-14 | 2016-09-29 | Nissan Chemical Ind Ltd | Active-ester-group-containing composition for producing fibers, and cell culture scaffold material using fibers produced from active-ester-group-containing composition |
| US20150290362A1 (en) * | 2014-04-10 | 2015-10-15 | Georgia Tech Research Corporation | Hybrid fibrin-microgel constructs for tissue repair and regeneration |
| US10589002B2 (en) * | 2014-04-14 | 2020-03-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biodegradable, thermally responsive injectable hydrogel for treatment of ischemic cardiomyopathy |
| KR101536134B1 (ko) | 2014-09-26 | 2015-07-14 | 세원셀론텍(주) | 연부조직 수복용 매트릭스의 제조방법 |
| US10265438B1 (en) * | 2014-11-03 | 2019-04-23 | BioDlogics, LLC | Methods and compositions for the repair and replacement of connective tissue |
| US9943403B2 (en) | 2014-11-19 | 2018-04-17 | Acufocus, Inc. | Fracturable mask for treating presbyopia |
| WO2016100500A1 (en) * | 2014-12-16 | 2016-06-23 | The Regents Of The University Of Colorado, A Body Corporate | Antimicrobial translimbal drainage device with replaceable filter |
| US11220669B2 (en) | 2015-06-05 | 2022-01-11 | Amolifescience Co., Ltd. | Defined three dimensional microenvironment for cell culture |
| US10687935B2 (en) | 2015-10-05 | 2020-06-23 | Acufocus, Inc. | Methods of molding intraocular lenses |
| CA3005891C (en) | 2015-11-24 | 2023-12-12 | Acufocus, Inc. | Toric small aperture intraocular lens with extended depth of focus |
| WO2017176930A1 (en) * | 2016-04-08 | 2017-10-12 | Emory University | Diphenylacrylic acid derivatives that promote bone and cartilage growth |
| WO2019099630A1 (en) * | 2017-11-16 | 2019-05-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gel for treating periocular and/or orbital pathologies and conditions |
| EP3790508A4 (en) | 2018-05-09 | 2022-02-09 | AcuFocus, Inc. | INTRAOCULAR IMPLANT WITH REMOVABLE OPTICS |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| KR102118807B1 (ko) * | 2018-11-26 | 2020-06-03 | 숭실대학교산학협력단 | 3차원 오가노이드 제조용 형상변화형 하이드로젤 몰드 조성물 및 이를 통해 제조된 몰드 |
| US11864990B2 (en) | 2019-02-26 | 2024-01-09 | Avedro, Inc. | Bioresorbable corneal implants |
| CN110292657A (zh) * | 2019-08-12 | 2019-10-01 | 郑州大学第一附属医院 | 一种用于组织修复的生物胶囊及其构建方法 |
| CN110694101A (zh) * | 2019-11-25 | 2020-01-17 | 高敏楠 | 医用伤口组织止血修复细胞胶水与胶带组合及方法 |
| CN112778474B (zh) * | 2020-12-28 | 2022-07-19 | 中国科学院苏州生物医学工程技术研究所 | 用于流式细胞术的稀土笼状配位物金属荧光双模标签及制备方法 |
| CN115144380B (zh) * | 2022-07-21 | 2024-08-09 | 清华大学 | 细胞牵引力的测量方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509606A (ja) * | 1992-06-04 | 1994-10-27 | ソシエテ・プロラボ | 官能化重合体超微粒子、その製法および用途 |
| JPH11189626A (ja) * | 1997-12-26 | 1999-07-13 | Unitika Ltd | 温度応答型ハイドロゲル |
| WO2000043539A2 (en) * | 1999-01-25 | 2000-07-27 | Biochip Technologies Gmbh | Immobilization of molecules on surfaces via polymer brushes |
| JP2002265540A (ja) * | 2001-03-14 | 2002-09-18 | Nippon Chem Ind Co Ltd | フルオロアルキル基含有オリゴマー類、その製造方法及び界面活性剤 |
| JP2003508606A (ja) * | 1999-09-08 | 2003-03-04 | スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン | 均一分子量ポリマー |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452925A (en) * | 1981-02-09 | 1984-06-05 | National Patent Development Corporation | Biologically stabilized compositions comprising collagen as the minor component with ethylenically unsaturated compounds used as contact lenses |
| US4780409A (en) * | 1985-05-02 | 1988-10-25 | Genetic Systems Corporation | Thermally induced phase separation immunoassay |
| US4835235A (en) * | 1986-01-24 | 1989-05-30 | Hoechst Celanese Corporation | Polyvinyl polymers exhibiting nonlinear optical response |
| DE3626160A1 (de) * | 1986-08-01 | 1988-02-04 | Basf Ag | Leimungsmittel fuer papier auf basis von fettalkyldiketenen und kationischen polyacrylamiden und terpolymerisate aus acrylamid, n-vinylimidazol und n-vinylimidazolin |
| US5653725A (en) * | 1990-07-12 | 1997-08-05 | University Of Miami | Instrument for initiating an intralamellar channel |
| US5200462A (en) * | 1991-01-25 | 1993-04-06 | Eastman Kodak Company | Succinimide containing polymers and lattices prepared from same |
| WO1992020721A1 (en) * | 1991-05-22 | 1992-11-26 | Kao Corporation | Process for producing both of ultraviolet-absorbent self-dispersible water-base vinyl resin and fine resin particle |
| US5276079A (en) * | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
| US5433745A (en) * | 1993-10-13 | 1995-07-18 | Allergan, Inc. | Corneal implants and methods for producing same |
| AU1014695A (en) * | 1994-02-17 | 1995-08-24 | Collagen Corporation | Collagen-synthetic polymer conjugates having controlled fiber size distributions |
| DE69636289T2 (de) * | 1995-12-18 | 2007-05-10 | Angiodevice International Gmbh | Vernetzten polymerisatmassen und verfahren für ihre verwendung |
| US6458889B1 (en) * | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| US6566406B1 (en) * | 1998-12-04 | 2003-05-20 | Incept, Llc | Biocompatible crosslinked polymers |
| US6030634A (en) * | 1996-12-20 | 2000-02-29 | The Chinese University Of Hong Kong | Polymer gel composition and uses therefor |
| US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
| US6103528A (en) * | 1998-04-17 | 2000-08-15 | Battelle Memorial Institute | Reversible gelling culture media for in-vitro cell culture in three-dimensional matrices |
| US6388047B1 (en) * | 1999-04-12 | 2002-05-14 | Cornell Research Foundation, Inc. | Hydrogel-forming system with hydrophobic and hydrophilic components |
| WO2000063268A1 (en) * | 1999-04-16 | 2000-10-26 | Wm. Marsh Rice University | Poly(propylene fumarate) cross linked with poly(ethylene glycol) |
| US6365171B1 (en) * | 1999-11-04 | 2002-04-02 | The University Of Akron | Amphiphilic networks, implantable immunoisolatory devices and methods of preparation |
| WO2001049824A2 (en) * | 2000-01-05 | 2001-07-12 | Novartis Ag | Cell growth substrate hydrogels |
| AU2001281485A1 (en) * | 2000-03-23 | 2001-10-03 | Genetics Institute, Inc. | Thermoreversible polymers for delivery and retention of osteoinductive proteins |
| AR030341A1 (es) * | 2000-08-14 | 2003-08-20 | Novartis Ag | Articulos biomedicos moldeados |
| WO2002039930A1 (fr) * | 2000-11-17 | 2002-05-23 | Menicon Co., Ltd. | Film a usage medical et procede de production de celui-ci, cornee artificielle faisant appel a ce film et procede de production de celle-ci |
| CA2453539A1 (en) * | 2001-07-13 | 2002-07-12 | Mebiol Inc. | Cell or tissue-culturing carrier, and culturing method |
-
2003
- 2003-08-11 EP EP06016006A patent/EP1741457A1/en not_active Withdrawn
- 2003-08-11 BR BR0313726-0A patent/BR0313726A/pt not_active IP Right Cessation
- 2003-08-11 WO PCT/CA2003/001180 patent/WO2004014969A1/en active IP Right Grant
- 2003-08-11 ES ES03783866T patent/ES2283849T3/es not_active Expired - Lifetime
- 2003-08-11 AU AU2003254674A patent/AU2003254674A1/en not_active Abandoned
- 2003-08-11 US US10/524,250 patent/US20060134050A1/en not_active Abandoned
- 2003-08-11 DE DE60312525T patent/DE60312525T2/de not_active Expired - Lifetime
- 2003-08-11 MX MXPA05001570A patent/MXPA05001570A/es unknown
- 2003-08-11 AT AT03783866T patent/ATE356838T1/de not_active IP Right Cessation
- 2003-08-11 JP JP2004526538A patent/JP2006516038A/ja active Pending
- 2003-08-11 KR KR1020057002380A patent/KR101053792B1/ko not_active IP Right Cessation
- 2003-08-11 CN CNB038240505A patent/CN100491424C/zh not_active Expired - Fee Related
- 2003-08-11 EP EP03783866A patent/EP1530600B1/en not_active Expired - Lifetime
-
2005
- 2005-11-25 HK HK05110713.0A patent/HK1078886A1/xx not_active IP Right Cessation
-
2006
- 2006-06-30 US US11/479,297 patent/US20060246113A1/en not_active Abandoned
-
2007
- 2007-10-19 JP JP2007273082A patent/JP2008093451A/ja active Pending
-
2014
- 2014-04-11 US US14/250,652 patent/US20150071871A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509606A (ja) * | 1992-06-04 | 1994-10-27 | ソシエテ・プロラボ | 官能化重合体超微粒子、その製法および用途 |
| JPH11189626A (ja) * | 1997-12-26 | 1999-07-13 | Unitika Ltd | 温度応答型ハイドロゲル |
| WO2000043539A2 (en) * | 1999-01-25 | 2000-07-27 | Biochip Technologies Gmbh | Immobilization of molecules on surfaces via polymer brushes |
| JP2003508606A (ja) * | 1999-09-08 | 2003-03-04 | スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン | 均一分子量ポリマー |
| JP2002265540A (ja) * | 2001-03-14 | 2002-09-18 | Nippon Chem Ind Co Ltd | フルオロアルキル基含有オリゴマー類、その製造方法及び界面活性剤 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006513744A (ja) * | 2002-12-19 | 2006-04-27 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド | 親水性コーティングを備えた生物医学装置 |
| JP2006515685A (ja) * | 2002-12-23 | 2006-06-01 | アルコン、インコーポレイテッド | 表面へのタンパク質吸着を抑制するためのｎ−イソプロピルアクリルアミド含有組成物および方法 |
| JP2007126490A (ja) * | 2005-11-01 | 2007-05-24 | Univ Of Tokushima | アミド基含有高分子化合物およびその製造方法 |
| WO2009034958A1 (ja) * | 2007-09-12 | 2009-03-19 | Jsr Corporation | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
| JP5387850B2 (ja) * | 2007-09-12 | 2014-01-15 | Ｊｓｒ株式会社 | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1688622A (zh) | 2005-10-26 |
| EP1530600B1 (en) | 2007-03-14 |
| ATE356838T1 (de) | 2007-04-15 |
| EP1741457A1 (en) | 2007-01-10 |
| HK1078886A1 (en) | 2006-03-24 |
| US20060134050A1 (en) | 2006-06-22 |
| KR20050083626A (ko) | 2005-08-26 |
| KR101053792B1 (ko) | 2011-08-04 |
| AU2003254674A1 (en) | 2004-02-25 |
| BR0313726A (pt) | 2005-06-14 |
| DE60312525D1 (de) | 2007-04-26 |
| US20150071871A1 (en) | 2015-03-12 |
| EP1530600A1 (en) | 2005-05-18 |
| MXPA05001570A (es) | 2005-08-19 |
| CN100491424C (zh) | 2009-05-27 |
| JP2008093451A (ja) | 2008-04-24 |
| US20060246113A1 (en) | 2006-11-02 |
| DE60312525T2 (de) | 2007-12-06 |
| WO2004014969A1 (en) | 2004-02-19 |
| ES2283849T3 (es) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101053792B1 (ko) | 생체 합성 매트릭스 및 그의 용도 | |
| MXPA05001543A (es) | Ligandos de receptores activados del proliferador de peroxisomas novedosos que no causan retencion de fluido, edema o insuficiencia cardiaca congestiva. | |
| JP5661722B2 (ja) | 眼用デバイス及びその製造方法 | |
| US20120071580A1 (en) | Suturable Hybrid Superporous Hydrogel Keratoprosthesis for Cornea | |
| EP3283510B1 (en) | Collagen mimetic peptide | |
| AU2003276137A1 (en) | Artificial cornea | |
| US20160144069A1 (en) | Suturable hybrid superporous hydrogel keratoprosthesis for cornea | |
| US20100080840A1 (en) | Hybrid superporous hydrogel scaffold for cornea regeneration | |
| US20060034807A1 (en) | Innervated artificial tissues and uses thereof | |
| KR102194155B1 (ko) | 온도 감응성 폴리머가 접합된 홍합 접착 단백질을 포함하는 온도 감응성 생체 소재 | |
| GB2540116A (en) | Novel peptide | |
| Kadakia et al. | Hybrid superporous scaffolds: an application for cornea tissue engineering | |
| CA2495132C (en) | Bio-synthetic matrix and uses thereof | |
| US20230355844A1 (en) | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060810 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060810 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091203 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100323 |